Tumor P70S6K hyperactivation is inversely associated with tumor-infiltrating lymphocytes in triple-negative breast cancer

Rebeca Jimeno(Universidad Complutense de Madrid), Miguel Quintela-Fandiño(Spanish National Cancer Research Centre), Roberto Salgado(Institut Jules Bordet), Luís Manso(Research Institute Hospital 12 de Octubre), Silvana Mourón(Spanish National Cancer Research Centre), Rodrigo Sánchez-Bayona(Research Institute Hospital 12 de Octubre), Belén Perez‐Mies(Universidad de Alcalá), Rámón Colomer(Hospital Universitario de La Princesa), Mario Martínez-López(Hospital Universitario 12 De Octubre), Rosario Serrano‐Pardo(Hospital Universitario de La Princesa), Ana Garrido-García(Hospital Universitario de La Princesa), Sherene Loi(The University of Melbourne)
Clinical & Translational Oncology
December 12, 2022
10.1007/s12094-022-03006-3
Cited by 1

Related Papers

Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
|The Lancet Oncology|2016|1.8k
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
|The Lancet|2020|1.8k
Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer
|New England Journal of Medicine|2015|1.6k
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
|Annals of Oncology|2021|1.4k
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
|New England Journal of Medicine|2019|1.3k